2-(bromomethyl)-6-(4-(trifluoromethyl)phenyl)pyridine | 638214-17-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(bromomethyl)-6-(4-(trifluoromethyl)phenyl)pyridine
• 英文别名: 2-(Bromomethyl)-6-[4-(trifluoromethyl)phenyl]pyridine
• CAS: 638214-17-2
• 化学式: C₁₃H₉BrF₃N
• 分子量: 316.12
• InChiKey: ZYEWPXGUBZAIMD-UHFFFAOYSA-N

物化性质

• 沸点：
  323.2±37.0 °C(Predicted)
• 密度：
  1.498±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(bromomethyl)-6-(4-(trifluoromethyl)phenyl)pyridine 在 甲醇 、 水 、 potassium carbonate 、 三乙胺 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 [6-[4-(Trifluoromethyl)phenyl]pyridin-2-yl]methanethiol
  参考文献：
  名称：

  [EN] CDK2 INHIBITORS AND METHODS OF USING THE SAME
  [FR] INHIBITEURS DE CDK2 ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.

  公开号：

  WO2024026483A2
• 作为产物：
  描述：

  2-溴-6-甲基吡啶 在 N-溴代丁二酰亚胺(NBS) 、 四(三苯基膦)钯 、 偶氮二异丁腈 、 二乙基亚磷酸氢酯 、 sodium carbonate 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 四氯化碳 、 水 、 乙腈 为溶剂， 反应 13.5h， 生成 2-(bromomethyl)-6-(4-(trifluoromethyl)phenyl)pyridine
  参考文献：
  名称：

  [EN] CDK2 INHIBITORS AND METHODS OF USING THE SAME
  [FR] INHIBITEURS DE CDK2 ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.

  公开号：

  WO2024026483A2

文献信息

• [EN] PHENYLALKANOIC ACID AND PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS<br/>[FR] ACIDE PHENYLALKANOIQUE ET DERIVES D'ACIDE PHENYLOXYALKANOIQUE EN TANT QU'ACTIVATEURS DE HPPAR
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2004000315A1

  公开（公告）日：2003-12-31

  The present invention provides a compound of formula (I):wherein:R1 and R2 are independently H or C1-3 alkyl;X represents a O or (CH2)n where n is 0, 1 or 2;R3and R4 independently represent H, C1-3 alkyl, -OCH3, -CF3, allyl, or halogen;X1 represents O, S, SO2, SO, or CH2;R5 and R6 independently represent hydrogen, C1-6 alkyl (including branched alkyl and optionally substituted by one or more halogens or C1-6alkoxy), or together with the carbon atom to which they are bonded form a 3-6 membered cycloalkyl ring;R7 represents a phenyl or a 6 membered heteroaryl group containing 1, 2 or 3 nitrogen atoms wherein the phenyl or heteroaryl group is substituted by 1, 2 or 3 moieties selected from the group consisting of halogen, C1-6 alkoxy, C1-6 alkyl, CF3, hydroxy, or phenyl (which may be optionally substituted by one or more C1-3 alkyl, -OC1-3 alkyl, CN, acetyl, hydroxy, halogen or CF3).

  本发明提供了一种具有以下结构的化合物(I)：其中：R1和R2分别独立地表示H或C1-3烷基；X代表O或(CH2)n，其中n为0、1或2；R3和R4独立地表示H、C1-3烷基、-OCH3、-CF3、烯丙基或卤素；X1代表O、S、SO2、SO或 ；R5和R6独立地表示氢、C1-6烷基（包括支链烷基，并且可以选择性地被一个或多个卤素或C1-6烷氧基取代），或者与它们键合的碳原子一起形成一个3-6环状烷基环；R7表示苯基或含有1、2或3个氮原子的6元杂芳基，其中苯基或杂芳基被选自卤素、C1-6烷氧基、C1-6烷基、 、羟基或苯基（可以选择性地被一个或多个C1-3烷基、-OC1-3烷基、CN、乙酰基、羟基、卤素或 取代）的1、2或3个取代基取代。
• Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators
  申请人：Bell Richard

  公开号：US20060089394A1

  公开（公告）日：2006-04-27

  A compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrolysable ester thereof, wherein:

  化合物的公式（I）或其药学上可接受的盐、溶剂化合物或可水解酯，其中：
• Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hPPAR activators
  申请人：SmithKline Beecham Corporation

  公开号：US07338960B2

  公开（公告）日：2008-03-04

  A compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrolysable ester thereof, wherein:

  化合物公式（I）或其药学上可接受的盐、溶剂化物或可水解酯，其中：
• Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]-N-[(piperidin-4-yl)methyl]methanamine (MMV019918) and analogues
  作者：Alessandra Vallone、Sarah D'Alessandro、Simone Brogi、Margherita Brindisi、Giulia Chemi、Gloria Alfano、Stefania Lamponi、Soon Goo Lee、Joseph M. Jez、Karin J.M. Koolen、Koen J. Dechering、Simona Saponara、Fabio Fusi、Beatrice Gorelli、Donatella Taramelli、Silvia Parapini、Reto Caldelari、Giuseppe Campiani、Sandra Gemma、Stefania Butini

  DOI：10.1016/j.ejmech.2018.03.024

  日期：2018.4

  Therapies addressing multiple stages of Plasmodium falciparum life cycle are highly desirable for implementing malaria elimination strategies. MMV019918 (1, 1-[5-(4-bromo-2-chlorophenyl)furan-2yl]-N-[(piperidin-4-yl)methyl]methanamine) was selected from the MMV Malaria Box for its dual activity against both asexual stages and gametocytes. In-depth structure-activity relationship studies and cytotoxicity evaluation led to the selection of 25 for further biological investigation. The potential transmission blocking activity of 25 versus P. falciparum was confirmed through the standard membrane feeding assay. Both 1 and 25 significantly prolonged atrioventricular conduction time in Langendorff-isolated rat hearts, and showed inhibitory activity of Ba2+ current through Ca(v)1.2 channels. An in silico target-fishing study suggested the enzyme phosphoethanolamine methyltransferase (PfPMT) as a potential target. However, compound activity against PfPMT did not track with the antiplasmodial activity, suggesting the latter activity relies on a different molecular target. Nevertheless, 25 showed interesting activity against PfPMT, which could be an important starting point for the identification of more potent inhibitors active against both sexual and asexual stages of the parasite. (C) 2018 Elsevier Masson SAS. All rights reserved.
• PHENYLALKANOIC ACID AND PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1513526B1

  公开（公告）日：2007-11-07